Roivant Sciences

ROIV · NASDAQ

$34.92+$0.22 (+0.63%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $34.70

About ROIV

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Employees: 750
Headquarters: London
Listed: Dec 3, 2020
Sector: Health Care
Industry: Biotechnology
Website: roivant.com

Leadership

Roivant Sciences executives
Name	Title	Since	Age
Ilan Oren	—	—	41
Mayukh Sukhatme	—	2021	49
Matthew Gline	—	2017	41
Richard Pulik	—	—	46
Frank Torti	—	—	46
Eric Venker	—	—	38
Jennifer Humes	—	—	44
Melissa Epperly	—	—	48
Meghan Fitzgerald	—	—	54
Daniel Gold	—	—	57
Keith Manchester	—	—	56
James Momtazee	—	—	53

Revenue by product and region

Fiscal year ended Mar 31, 2024: $124.80M total revenue

By product

Product revenue, net [Member]$75.06M60.1%
Represents the license, milestone, and other revenue.$24.90M20.0%

Similar companies

Companies in the same industry as Roivant Sciences

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.